New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus Cision · Sep 28, 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Cision · Sep 28, 2026
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Cision · Sep 28, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cision · Sep 26, 2026
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cision · Sep 26, 2026
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration Cision · Sep 26, 2026
ZYUS Life Sciences Corporation Announces Planned Release Date for Phase 2a Clinical Trial Results, Annual General Meeting Results and Change in Audit Committee Chair Cision · Sep 25, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Cision · Sep 25, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma Cision · Sep 25, 2026
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Cision · Sep 25, 2026
